Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Cash from Investing Activities (2017 - 2025)

Historic Cash from Investing Activities for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $40.0 million.

  • Sutro Biopharma's Cash from Investing Activities fell 7285.02% to $40.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.8 million, marking a year-over-year increase of 585.26%. This contributed to the annual value of $218.5 million for FY2024, which is 566850.15% up from last year.
  • Sutro Biopharma's Cash from Investing Activities amounted to $40.0 million in Q3 2025, which was down 7285.02% from $2.6 million recorded in Q2 2025.
  • Sutro Biopharma's 5-year Cash from Investing Activities high stood at $147.3 million for Q3 2024, and its period low was -$121.7 million during Q1 2021.
  • In the last 5 years, Sutro Biopharma's Cash from Investing Activities had a median value of $5.9 million in 2021 and averaged $5.7 million.
  • Within the past 5 years, the most significant YoY rise in Sutro Biopharma's Cash from Investing Activities was 71543.57% (2022), while the steepest drop was 338068.69% (2022).
  • Sutro Biopharma's Cash from Investing Activities (Quarter) stood at $20.8 million in 2021, then crashed by 282.29% to -$37.9 million in 2022, then soared by 37.93% to -$23.5 million in 2023, then soared by 472.08% to $87.5 million in 2024, then plummeted by 54.29% to $40.0 million in 2025.
  • Its last three reported values are $40.0 million in Q3 2025, $2.6 million for Q2 2025, and -$16.3 million during Q1 2025.